Direct-acting antivirals (DAAs) for the treatment of HCV have dramatically increased the rate of sustained virological response: patients not achieving sustained virological response represent a challenge and rates of late recurrent viremia are very low. We describe here the first case of a very late HCV relapse, following an atypical kinetics (characterized by a spontaneous but transient HCV clearance after an early virological relapse), in a HIV co-infected patient treated with DAAs. Optimal adherence to the therapy was well documented and a phylogenetic analysis ruled out a possible reinfection from a different HCV strain. In conclusion, our case underlines the importance of a long follow-up (>48 weeks) after DAAs therapies in HCV-HIV co-infected patients who might benefit the most from a very rigorous virological surveillance.

Guardigni, V., Cento, V., Ianniruberto, S., Badia, L., Aragri, M., Conti, M., et al. (2018). HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals. INFECTION, 46(5), 717-720 [10.1007/s15010-018-1158-9].

HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals

Conti M.;Perno C. F.;Ceccherini-Silberstein F.;
2018-01-01

Abstract

Direct-acting antivirals (DAAs) for the treatment of HCV have dramatically increased the rate of sustained virological response: patients not achieving sustained virological response represent a challenge and rates of late recurrent viremia are very low. We describe here the first case of a very late HCV relapse, following an atypical kinetics (characterized by a spontaneous but transient HCV clearance after an early virological relapse), in a HIV co-infected patient treated with DAAs. Optimal adherence to the therapy was well documented and a phylogenetic analysis ruled out a possible reinfection from a different HCV strain. In conclusion, our case underlines the importance of a long follow-up (>48 weeks) after DAAs therapies in HCV-HIV co-infected patients who might benefit the most from a very rigorous virological surveillance.
2018
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA
English
Antiviral therapy; HIV infection; Hepatitis; IFN-free regimens; Maraviroc; Recurrence; Antiviral Agents; Genotype; HIV Infections; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Phylogeny; RNA, Viral; Recurrence; Treatment Outcome; Coinfection; Viral Load
Guardigni, V., Cento, V., Ianniruberto, S., Badia, L., Aragri, M., Conti, M., et al. (2018). HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals. INFECTION, 46(5), 717-720 [10.1007/s15010-018-1158-9].
Guardigni, V; Cento, V; Ianniruberto, S; Badia, L; Aragri, M; Conti, M; Perno, Cf; Viale, P; Ceccherini-Silberstein, F; Verucchi, G
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/219581
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact